Modera Wealth Management LLC Has $5.90 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Modera Wealth Management LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,278 shares of the biopharmaceutical company’s stock after selling 169 shares during the period. Modera Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,896,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in REGN. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $49,000. Finally, Larson Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 127.3% during the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 28 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN stock opened at $698.74 on Monday. The firm has a 50-day moving average price of $698.51 and a 200-day moving average price of $866.13. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $76.39 billion, a P/E ratio of 18.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.86 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.